Actionable news
0
All posts from Actionable news
Actionable news in DEPO: Depomed, Inc.,

Prospectuses and communications, business combinations

BGCOLOR="WHITE">

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2015

Horizon Pharma Public Limited Company

(Exact name of registrant as specified in its charter)

Connaught House, 1 st Floor, 1 Burlington Road, Dublin 4, Ireland

(Address of principal executive offices)

Registrants telephone number, including area code: 011-353-1-772-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), expired effective Friday, October 9, 2015, with respect to the proposed acquisition of Depomed, Inc. (Depomed) by Horizon Pharma plc (Horizon Pharma).

As previously announced on September 8, 2015, Horizon Pharma commenced an exchange offer for all of the outstanding shares of Depomed common stock. Under the terms of the offer, tendering Depomed shareholders would be able to exchange each share of Depomed common stock for 0.95 Horizon Pharma ordinary shares. The expiration of the HSR waiting period satisfies one of the conditions required to consummate the offer. Other conditions remain to be satisfied, including, among others, the redemption or removal of certain poison pill rights that the...


More